Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIMBOW vs RELVAR in COPD
NCT04671355Phase 4Withdrawn
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Inhalation Devices, Small Molecules
01
Overview
Phase 4, randomised, open-label trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Area Under the Reactance Curve at 4 weeks. Planned start Oct 2021; status: withdrawn.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04671355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04671355.